A Multicenter, Randomized, Outcomes Assessor Blind, Parallel Controlled Trial to Evaluate the Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After Coronary Artery Bypass Grafting

The goal of this clinical trial is to to evaluate the effect of oral isosorbide mononitrate plus amlodipine antispasm therapy on outcomes of radial artery grafts in patients underwent primary isolated CABG.
The main question it aims to answer is:
Whether the oral isosorbide mononitrate plus amlodipine antispasm therapy could reduce the failure outcome of radial artery grafts after CABG .
Researchers will compare isosorbide mononitrate plus amlodipine to none to see if isosorbide mononitrate plus amlodipine works.
Participants will
1. Take oral isosorbide mononitrate (20-40mg daily) plus amlodipine (2.5-5mg daily) therapy for 24 weeks after CABG.
2. Clinical follow-up at Week 1, 4, 12, and 24 after CABG.
3. Protocol-driven CCTA at Week 24 after CABG.

Start Date01 Jun 2025

Sponsor / Collaborator-

ISRCTN44436843

/ RecruitingPhase 3IIT

The LACunar Intervention Trial 3 (LACI-3). Assessment of efficacy and safety of cilostazol and isosorbide mononitrate to prevent adverse outcomes in patients with cerebral small vessel disease (lacunar) ischaemic stroke.

Start Date03 Mar 2025

Sponsor / Collaborator

The University of Edinburgh

[+1]

NCT06715007

/ RecruitingNot ApplicableIIT

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).

Start Date20 Dec 2024

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

100 Clinical Results associated with Isosorbide Mononitrate

100 Translational Medicine associated with Isosorbide Mononitrate

100 Patents (Medical) associated with Isosorbide Mononitrate

1,790

Literatures (Medical) associated with Isosorbide Mononitrate

01 Sep 2025·INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A Matched Case-Control Study of the Relationship Between Radiation Dose to the Internal Mammary Lymph Nodes and Clinical Outcomes in Patients With and Without Internal Mammary Lymph Node Relapses

Article

Author: Lohrisch, Caroline ; Gondara, Lovedeep ; Swift, Carrie-Lynne ; Nichol, Alan ; Chng, Nicholas ; Musoke, Richard ; Narinesingh, Dylan ; Chang, Jee Suk ; Wade, Louise ; Speers, Caroline

PURPOSE:

The Early Breast Cancer Trialists' Collaborative Group's 2023 meta-analysis of radiation therapy to regional nodes in early breast cancer demonstrated a significant improvement in overall survival (OS) without an associated improvement in locoregional recurrence in the trials comparing internal mammary node (IMN) irradiation versus none. We aimed to study cases with IMN relapse (IMNR) and controls without IMNR to examine the link between IMNR and OS.

METHODS AND MATERIALS:

Patients treated curatively between 2005 and 2014, who subsequently developed IMNR, were identified in a population-based database. The IMNR cases were matched 1:2 to controls without IMNR using patient and tumor characteristics. The internal mammary vessels in the first 3 intercostal spaces were outlined on planning computed tomography scans as the IMN clinical target volume, and the mean equivalent doses in 2-Gy fractions to the IMNs were calculated. Multivariable Fine and Gray competing-risk regression and Cox regression were used to evaluate the effect of the baseline patient, tumor, and treatment variables, including therapeutic IMN irradiation with ≥40 Gy on IMNR and OS.

RESULTS:

Seventy cases were matched with 140 controls. Median follow-up was 9.1 years, median tumor size was 25 mm, and N-stages were: 37% N0, 33% N1, and 30% N2-3. The medians of the IMN doses were 4.1 Gy for cases and 13.7 Gy for controls (P < .001). On multivariable analysis, worse IMNR was associated with mastectomy (hazard ratio [HR], 2.11; P = .02), and better IMNR was associated with therapeutic IMN irradiation (HR, 0.36; P = .009); worse OS was associated with larger tumor size (HR, 1.02; P = .006), ≥10 positive axillary nodes (HR, 3.15; P = .04), and triple-negative subtype (HR, 2.92; P = .03), and better OS was associated with therapeutic IMN irradiation (HR, 0.49; P = .02).

CONCLUSIONS:

We demonstrated that therapeutic IMN irradiation with ≥40 Gy was associated with both a lower risk of IMNR and improved OS.

08 Aug 2025·ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY

Wedge fragments: no significant impact on bone healing in femoral shaft fractures treated with intramedullary nailing.

Article

Author: Yoon, Yong-Cheol ; Jang, Myung Jin ; Song, Hyung Keun ; Jeun, Jigang

INTRODUCTION:

Intramedullary nailing (IMN) is the treatment of choice for femoral shaft fractures with wedge-shaped fragments. However, the management of wedged fragments remains controversial. This study investigated whether wedged fragments affect bone union rates in patients treated with IMN. The primary hypothesis was that wedged fragments would not significantly affect bone union when proper IMN principles were followed.

MATERIALS AND METHODS:

Between March 2014 and June 2023, 162 patients were diagnosed with femoral shaft fractures (AO/OTA 32-B type) accompanied by wedge fractures. The surgeries involved the use of a reconstruction antegrade nail with a greater trochanteric entry point. Closed reduction was performed, and recon-type screws were used for proximal fixation of the femoral neck and head and at least two screws distally. The wedged fragments were not manipulated further. We analyzed the characteristics of the wedged fragments, including size, displacement, angle, and reversal morphology, and assessed the main fracture gap size in relation to bone union outcomes.

RESULTS:

The study included 95 of the 162 patients, of whom 82 (86.3%) achieved bone union and 13 (13.7%) experienced nonunion. Demographic and preoperative variables showed no significant differences between the union and nonunion groups. Postoperative radiographic analysis of the wedged fragments revealed no significant differences in fragment size, angle, displacement, or presence of reversed fragments. However, the main fracture gap size significantly differed, averaging 5.2 mm in the union group and 15.6 mm in the nonunion group(p = 0.01). Complications included superficial infections in four patients and malrotation in three, which were managed conservatively.

CONCLUSIONS:

Wedge fragments in femoral shaft fractures do not significantly affect bone union with IMN. Instead, the size of the main fracture gap is critical for healing. Surgery should focus on stable fixation and minimization of the main fracture gap rather than manipulating the wedged fragments.

01 Aug 2025·Journal of the Pediatric Orthopaedic Society of North America

Outcomes of Suprapatellar Intramedullary Nail Fixation of Tibial Shaft Fractures in Skeletally Immature Patients

Article

Author: Kelly, Derek M ; Rowland, Jonathan K ; Coble, Tori J ; Spence, David D ; Pargas-Colina, Carlos D ; Davis, Sara E ; Sheffer, Benjamin W

Background:

Tibial shaft fractures in children require individualized treatment approaches, including elastic nails, plates and screws, intramedullary rigid nails (IMN), and external fixators, with selection based on fracture characteristics and patient factors. IMN risks damaging the physis, but can provide enhanced stability and immediate weight bearing. While both infrapatellar and suprapatellar approaches exist for IMN placement, studies in adults have demonstrated that the suprapatellar approach offers higher patient satisfaction, less anterior knee pain, and lower radiation exposure. However, there is a lack of data on IMN for pediatric tibial fractures.

Methods:

This single-center, retrospective cohort study analyzed patients aged 11-16 with open proximal tibia physis and tibial shaft fractures treated with IMN via the suprapatellar approach from January 2016 to October 2023. Demographic, fracture, and operative data were collected, and proximal tibial angles were measured. Follow-up radiographs were evaluated for tibial growth and alignment, with malunion defined as over 5 degrees of angular deformity.

Results:

Thirty-five patients aged 11 to 16 (mean 14.7 years, SD 1.1) met the inclusion criteria. Males comprised 60%; the average follow-up was 12.4 months. Most fractures (74%, 26/35) were closed. The most common (57%) fracture pattern was OA42A1-3. Fracture union occurred by 9 weeks in 79% of cases. The mechanical Medial Proximal Tibial Angle (mMPTA, range 85-90 degrees) and Posterior Proximal Tibial Angle (PPTA, range 77-84 degrees) were normal in all pre-operative patients; there were no statistically significant changes in mMPTA and PPTA over the follow-up period. The reported Visual Analog Scale pain scale averaged 1.87 at the final follow-up. Most patients reported return to full activities (87%), with the operative leg comparable to the contralateral leg in 78% of cases.

Conclusions:

Our findings demonstrated that suprapatellar IMN insertion leads to low pain scores and good function in short-term follow-up for adolescent patients treated for tibial shaft fractures. No proximal tibia growth disturbance was detected. Further prospective studies are warranted.

Key Concepts:

(1)The suprapatellar approach appears to be safe for adolescent tibial nailing.(2)Growth disturbance was not encountered in this carefully selected patient group.(3)Radiographic tibial fracture union was achieved in call patients in this cohort.

Level of Evidence:

Level IV.

News (Medical) associated with Isosorbide Mononitrate

14 Aug 2025

·www.prnewswire.com

Navamedic ASA: Financial report for the 2nd quarter and first half of 2025

OSLO, Norway, Aug. 14, 2025 /PRNewswire/ -- In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 269.3 million, down from NOK 277.2 million in 2024. Excluding the milestone license fee from Orion corporation of NOK 22.7 million in 2024, revenues grew by 5.8 per cent YoY, gross margin improved to 37.3 per cent, compared to 37.0 per cent in Q2 2024 and EBITDA amounted to NOK 22.9 million compared to EBITDA of NOK 18.4 million in 2024. The performance was primarily driven by the Hospital area, particularly the antibiotics portfolio. Recent tender wins have driven sales growth for the antibiotics portfolio, which is up 48.4% YoY. "Having invested in various strategic growth initiatives over the last year, we are encouraged by the results in the second quarter of 2025. Excluding the Orion license fee last year, the 5.8 per cent revenue growth was positively impacted by Nordic tender wins for our antibiotics portfolio. Furthermore, several products, including Imdur® from our Prescription Drugs (RX) segment, have shown strong performance this quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic. "We are also pleased to announce approval of the medical device OraFID® as primary package for Flexilev®, our medical treatment for Parkinson disease, enabling personalized, fine-tuned treatment with minitablets," she added. Business area update and Q2 key figures During the second quarter, the Hospital (up 23.5 per cent YoY) business area delivered strong growth. Prescription Drugs and Consumer Health were down 2.8 and 3.5 per cent YoY respectively in the period. As part of the Prescription Drugs (RX) area, revenues of Imdur® delivered strong revenues in the period and is up 101.0% YoY. Flexilev®, the company's unique treatment for Parkinson's disease, delivered sales growth of 4.8 per cent YoY. Mysimba® revenues were lower than last year by 12% YTD, while variable between the quarters (-26.6% YoY). For the Hospital area, recent tender wins drove sales growth in the antibiotics portfolio, which is up 48.4 per cent YoY, whilst the Medical Nutrition portfolio showed 3.3.% growth. The company's third business area, Consumer Health, delivered mixed results (-3.5%). Revenues of Modifast were slightly down (-1.1%), whilst Eroxon® saw a 10.7 per cent increase in revenues. Operating results (EBIT) for the second quarter of 2025 amounted to NOK 6.3 million, compared to NOK 6.2 million in 2024, excluding milestone license fee. Operating costs ended at NOK 41.1 million, compared to NOK 39.4 million last year. Net financial items ended at negative NOK 8.1 million and profit before tax was negative NOK 1.5 million. Outlook Navamedic continues to see growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "The past six months have been marked by execution across multiple fronts, from product and company acquisitions to successful launches and impactful marketing initiatives. Several initiatives, such as the dne pharma acquisition, will take time to translate into our growth results but with a solid foundation and continued operational progress, we are well-positioned to realize our ambition of reaching NOK 1 billion in revenue," Andreassen concluded. Presentation Navamedic will present the results for the second quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision . The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionFinancial StatementDrug Approval

30 Apr 2025

·www.prnewswire.com

Navamedic Q1 2025: Strong start of the year and well-positioned for future growth

OSLO, Norway, April 30, 2025 /PRNewswire/ -- In the first quarter of 2025, Navamedic ASA (OSE: NAVA) , a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, reported revenues of NOK 132.0 million, representing a 9.2 per cent increase from the same period in 2024. EBITDA reached NOK 12.8 million, up from NOK 8.5 million last year. Gross margin improved to 40.7per cent, compared to 38.7per cent in Q1 2024. The strong performance was primarily driven by the Hospital area, particularly the antibiotics portfolio, supported by two long-term Nordic tenders secured in 2024. The company also experienced double-digit revenue growth in its Prescription Drugs (RX) area, contributing to the overall growth. "After investing in several strategic growth initiatives last year, we are pleased to see strong results already in the first quarter of 2025. The positive impact of the Nordic tender wins for our antibiotics portfolio has just begun to materialize. In addition, several products, including Mysimba® and Imdur® from our Prescription Drugs (RX) segment, delivered strong performance in the quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic. "We are also pleased to announce the renewal of our agreement with TopRidge Pharma, securing the exclusive rights to market and sell Imdur® for another eight years. Over the past few years, we have systematically expanded and matured our product portfolio while investing in initiatives to drive future growth. The strong start to 2025 confirms the progress we are making," she added. Business area update and Q1 key figures During the first quarter, the Prescription Drugs (up 11.5 per cent YoY) and Hospital (up 15.2 per cent YoY) business areas delivered strong growth. Consumer Health had a steady development in the period (up 0.3 per cent YoY). As part of the Prescription Drugs area, revenues of Mysimba® increased by 7.3 per cent YoY. During the quarter, the European Medicines Agency's Human Medicines Committee also announced its review of Mysimba®. It affirmed that the benefits continue to outweigh the risks for weight management in adults with obesity or overweight. Imdur® and Nitrolingual® performed well in the quarter and were up 54 per cent and 22 per cent, respectively. Flexilev®, the company's unique treatment for Parkinson's Disease, delivered sales growth of 13 per cent YoY. Forlax® had a revenue decrease of 45 per cent due increased competition. For the Hospital area, the two tender wins drove sales growth in the antibiotics portfolio, which is up 32 per cent YoY, whilst the Medical Nutrition portfolio maintained steady sales. The company's third business area, Consumer Health, delivered stable results. Revenues of Modifast were steady during Q1, whilst Absolut Torr (up 49 per cent YoY) and ThermaCare (up 8 per cent YoY) experienced strong growth. Eroxon® saw a 9 per cent decrease in revenues, which is explained by a stock build-up in Q1 2024. Operating results (EBIT) for the first quarter of 2025 amounted to NOK 9.1 million, compared to NOK 4.9 million in 2024. Operating costs ended at NOK 40.9 million, compared to NOK 38.3 million last year. Net financial items ended at negative NOK 11 million and profit before tax was negative NOK 1.8 million. Outlook Navamedic continues to see strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "We have had a strong start to 2025. We have several key hero products across our three business areas, many of which have the potential to succeed internationally. Part of our work moving forward will be to identify growth opportunities for these products to support future growth," Andreassen concluded. Presentation Navamedic will present the results for the first quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Financial Statement

29 Apr 2025

·www.pharmaindustrial-india.com

Navamedic Extends Imdur Distribution Agreement Until 2032

Navamedic ASA has signed a renewed distribution agreement with TopRidge Pharma Limited (TopRidge) for Imdur®, valid until June 2032, including options for new products to be added to the agreement. "It is a pleasure to announce that we have agreed with our great partner TopRidge Pharma, to revise and renew the distribution agreement for Imdur until 2032. Imdur is our second largest single brand and is currently marketed by us in the Nordics, the Netherlands, the Baltics, Greece and Cyprus. Although there is generic competition in this field, the original product is highly valued by the patients who often stay on the treatment for a long period of time," said Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic. Imdur® (isosorbide mononitrate), is a prescription medication used to prevent angina pectoris due to heart disease. It was first launched in Europe in 1985. Navamedic commenced distribution of the product as part of a strategic partnership and long-term distribution agreement with TopRidge Pharma Limited in 2016. "Imdur® remains an important product to Navamedic, and we appreciate the efforts made by TopRidge to update the Marketing Authorisations and to secure steady supplies to our markets. With the renewal of this agreement, we look forward to exploring further collaboration opportunities for additional products in the future," added Gamborg Andreassen.

Drug ApprovalLicense out/in

100 Deals associated with Isosorbide Mononitrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00630	Isosorbide Mononitrate	C01DA14	DB01020

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	China	Livzon Group Livzon Pharmaceutical Factory	01 Jan 1993
Angina Pectoris	United States	Promius Pharma LLC	30 Dec 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina, Stable	Phase 3	Brazil	Laboratórios Baldacci SA	01 Jul 2014
Myocardial Infarction	Phase 1	China	-	10 Oct 2013
Vasospasm	Phase 1	China	-	10 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03451591 (LACI-2, CTgov)	Phase 2/3	Stroke, Lacunar	363	Isosorbide Mononitrate (Isosorbide Mononitrate XL (ISMN))	alqcsspvdd = hlxuiplozw zkszcymmda (wzmrfyleaz, seukcmcgls - yxchmsffdm) View more	-	12 Nov 2024
				Cilostazol (Cilostazol)	alqcsspvdd = jguiugcmmm zkszcymmda (wzmrfyleaz, lxeueynpro - lhtfrrhpda) View more
NCT04310995 (ASRAB-pilot, ESC2024)	Phase 4	complication of coronary artery bypass graft	150	Nicorandil 15 mg daily	bczvuoijqc(faqyggwpmf) = zbuvyovwpo kpanaygvrj (gabrkbtbrq ) View more	Negative	30 Aug 2024
				Isosorbide mononitrate 50 mg daily	bczvuoijqc(faqyggwpmf) = fcwgeowvgf kpanaygvrj (gabrkbtbrq ) View more
NCT04051957 (CTgov)	Phase 2	Kidney Diseases \| Proteinuria \| Hypertension	9	Isosorbide Mononitrate (Isosorbide Mononitrate)	ubenmjvrqz = fgpvbqzamx eftpboidnf (yznxaxqjtn, dcbszfotlw - cklaeplslu) View more	-	03 Aug 2022
				Placebo oral tablet (Placebo)	ubenmjvrqz = dvswiecxcb eftpboidnf (yznxaxqjtn, ryoamiirrv - oevinxclga) View more
NCT03171480 (NOPE, CTgov)	Phase 4	Obstetric Labor, Premature \| Pre-Eclampsia	176	Monoket Pill (Monoket Pill)	kzkzsvwlbr = kmkhvjhgar wabyfbccyg (edijmipehw, dzxjanpwvg - axrajkulhu) View more	-	04 Jan 2022
				Placebo (Placebo Pill)	aueradxfuj = yhyiqxaszy cdspjbionz (xtgvxpvsnm, gdjpubprcj - izoxwajwqa) View more
NCT03171480 (Pubmed \| Am J Obstet Gynecol MFM)	Phase 4	Hypertension	176	Vaginal Isosorbide Mononitrate	zmmsvsijjx(veanlpvpdh) = qccnqvgwxf ppvihhmiwg (hhewxmpyof ) View more	Negative	27 Feb 2021
				Placebo	zmmsvsijjx(veanlpvpdh) = nxfkoesdoe ppvihhmiwg (hhewxmpyof ) View more
NCT02791906 (CTgov)	Phase 2	Chronic Kidney Diseases	8	ISMN (ISMN Only)	wuyuiwymni(xlptvnbaga) = xsubfqeolo olqykvtbsb (sapqasjciz, 31.5) View more	-	13 Aug 2020
				Vitamin C+ISMN (ISMN AND Vitamin C)	wuyuiwymni(xlptvnbaga) = mjrshplukb olqykvtbsb (sapqasjciz, 1.26) View more
NCT02053493 (NEAT-HFpeF, CTgov)	Phase 2	Heart Failure	110	Placebo+Isosorbide Mononitrate (Isosorbide Mononitrate Crossover to Placebo)	alhpbgzvvq(asrncyclcn) = rujbaoggha fwkntwimit (cljcdwlazu, 4601) View more	-	28 Nov 2016
				Placebo+Isosorbide Mononitrate (Placebo Crossover to Isosorbide Mononitrate)	alhpbgzvvq(asrncyclcn) = efptqxmdwg fwkntwimit (cljcdwlazu, 6286) View more
NCT02053493 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 2	Heart Failure	110	Isosorbide Mononitrate	gcocfzamlr(oiokogxvmj) = qxargnacad idejszsuoh (ihziydblie, -780 to 17) View more	Negative	10 Dec 2015
				Placebo	-
NCT01430780 (Pubmed \| Coron Artery Dis)	Not Applicable	Coronary Artery Disease	60	ISMN 20 mg retarded release	oerghgzhyo(wmbjenwybw) = nbyvjagidr utmeowrvio (lbykyasnef )	Negative	01 Nov 2013
				Placebo	oerghgzhyo(wmbjenwybw) = coiuxcjumn utmeowrvio (lbykyasnef )
ISRCTN39772441 (IMOP study, Pubmed \| BJOG)	Not Applicable	-	-	Isosorbide mononitrate (IMN)	imgqbdvjbl(swvsofjnbz): mean difference = -1.6 (95% CI, -5.1 to 1.9), P-Value = 0.37	Positive	01 Aug 2009
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Isosorbide Mononitrate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation